ATE277189T1 - Verfahren zur herstellung von protein mutanten mit reduzierter allergener wirkung in menschen. - Google Patents

Verfahren zur herstellung von protein mutanten mit reduzierter allergener wirkung in menschen.

Info

Publication number
ATE277189T1
ATE277189T1 AT99918575T AT99918575T ATE277189T1 AT E277189 T1 ATE277189 T1 AT E277189T1 AT 99918575 T AT99918575 T AT 99918575T AT 99918575 T AT99918575 T AT 99918575T AT E277189 T1 ATE277189 T1 AT E277189T1
Authority
AT
Austria
Prior art keywords
humans
producing protein
protein mutants
reduced allergenic
allergenic effects
Prior art date
Application number
AT99918575T
Other languages
English (en)
Inventor
David A Estell
Fiona A Harding
Original Assignee
Genencor Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22032273&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE277189(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genencor Int filed Critical Genencor Int
Application granted granted Critical
Publication of ATE277189T1 publication Critical patent/ATE277189T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Detergent Compositions (AREA)
AT99918575T 1998-04-15 1999-04-14 Verfahren zur herstellung von protein mutanten mit reduzierter allergener wirkung in menschen. ATE277189T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/060,872 US6835550B1 (en) 1998-04-15 1998-04-15 Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
PCT/US1999/008253 WO1999053038A2 (en) 1998-04-15 1999-04-14 Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins

Publications (1)

Publication Number Publication Date
ATE277189T1 true ATE277189T1 (de) 2004-10-15

Family

ID=22032273

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99918575T ATE277189T1 (de) 1998-04-15 1999-04-14 Verfahren zur herstellung von protein mutanten mit reduzierter allergener wirkung in menschen.
AT04016880T ATE452195T1 (de) 1998-04-15 1999-04-14 Protease mutanten mit reduzierter allergener wirkung in menschen und methoden zur konstruktion,identifizierung und herstellung dieser proteasen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04016880T ATE452195T1 (de) 1998-04-15 1999-04-14 Protease mutanten mit reduzierter allergener wirkung in menschen und methoden zur konstruktion,identifizierung und herstellung dieser proteasen

Country Status (20)

Country Link
US (4) US6835550B1 (de)
EP (3) EP1586649B1 (de)
JP (1) JP4447774B2 (de)
KR (1) KR20010034776A (de)
CN (1) CN1302113C (de)
AT (2) ATE277189T1 (de)
AU (1) AU752934B2 (de)
BR (1) BR9909640A (de)
CA (1) CA2327311C (de)
CZ (1) CZ20003789A3 (de)
DE (3) DE69920434D1 (de)
DK (3) DK1073754T3 (de)
ES (2) ES2338319T3 (de)
ID (1) ID26645A (de)
IL (2) IL138445A0 (de)
MX (2) MXPA05003289A (de)
NO (1) NO20005153L (de)
NZ (2) NZ506926A (de)
PL (1) PL343509A1 (de)
WO (1) WO1999053038A2 (de)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750329B1 (en) * 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
US6967080B1 (en) * 1990-12-05 2005-11-22 Novozymes A/S Proteins with changed epitopes and methods for the production thereof
US20050209121A1 (en) * 1990-12-05 2005-09-22 Novozymes A/S Proteins with changed epitopes and methods for the production thereof
MA23346A1 (fr) * 1993-10-14 1995-04-01 Genencor Int Variantes de la subtilisine
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
US6642011B2 (en) * 1998-04-15 2003-11-04 Genencor International, Inc. Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins
US6838269B1 (en) * 1998-04-15 2005-01-04 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6936249B1 (en) 1998-04-15 2005-08-30 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
CA2249648A1 (en) * 1998-11-04 2000-05-04 Nabil G. Seidah Mammalian subtilisin/kexin isozyme ski-1: a proprotein convertase with a unique cleavage specificity
US6946128B1 (en) * 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
AU6085800A (en) * 1999-07-22 2001-02-13 Procter & Gamble Company, The Subtilisin protease variants having amino acid substitutions in defined epitope regions
KR20020021397A (ko) * 1999-07-22 2002-03-20 데이비드 엠 모이어 규정된 에피토프 영역에 아미노산 결실 및 치환을 갖는서브틸리신 프로테아제 변이체
DE60028248T2 (de) * 1999-12-02 2007-03-15 Thromb-X N.V. Verfahren zur Reduzierung der Immunogenität von Staphylokinase durch Entfernen von T-Zell-Epitopen
WO2001041786A1 (en) 1999-12-10 2001-06-14 The General Hospital Corporation METHODS TO STIMULATE INSULIN PRODUCTION BY PANCREATIC β-CELLS
DE60115602T2 (de) * 2000-02-08 2006-08-10 Dsm Ip Assets B.V. Verwendung von säurestabilen subtilisinproteasen in tierfutter
US6960462B2 (en) 2000-02-08 2005-11-01 Dsm Ip Assets B.V Use of acid-stable subtilisin proteases in animal feed
US6855548B2 (en) 2000-02-08 2005-02-15 F. Hoffman-La Roche Ag Use of acid-stable proteases in animal feed
WO2001083559A2 (en) * 2000-04-28 2001-11-08 Novozymes A/S Production and use of protein variants having modified immunogenecity
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
CA2437265A1 (en) * 2001-02-06 2002-08-15 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified leptin with reduced immunogenicity
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
EP1239032A1 (de) * 2001-03-02 2002-09-11 Société des Produits Nestlé S.A. Milchsäurebakterien als Mitteln zur Behandlung und Vorbeugung von Allergie
DK1373296T3 (da) * 2001-03-23 2012-01-09 Procter & Gamble Proteiner, der frembringer et ændret immunogent respons, og fremgangsmåder til fremstilling og anvendelse deraf
WO2002096454A1 (en) * 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2002098454A2 (en) * 2001-05-31 2002-12-12 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
NZ530582A (en) 2001-07-17 2008-06-30 Res Dev Foundation Therapeutic agents comprising pro-apoptotic proteins, including granzyme, bax and TNF
US7157416B2 (en) * 2001-07-20 2007-01-02 Genencor International, Inc. Stabilization of enzymes
MXPA04004417A (es) * 2001-11-12 2004-08-11 Merck Patent Gmbh Anticuerpo anti-tnf alfa modificado.
WO2003042656A2 (en) * 2001-11-13 2003-05-22 Genencor International, Inc. Identifying and reducing the allergenicity of food proteins
WO2003057246A1 (en) * 2001-12-31 2003-07-17 Genencor International, Inc. Proteases producing an altered immunological response and methods of making and using the same
JP4597528B2 (ja) * 2002-02-26 2010-12-15 ジェネンコー・インターナショナル・インク 免疫原性が減少したズブチリシン・カールスバーグタンパク質
NZ534198A (en) * 2002-02-26 2005-11-25 Genencor Int Population based assessments and means to rank the relative immunogenicity of proteins
EP2341070A3 (de) 2002-03-29 2011-10-19 Genencor International, Inc. Verstärkte Proteinexpression in Bacillus
WO2003087161A1 (en) * 2002-04-18 2003-10-23 Merck Patent Gmbh Modified factor viii
DE60332556D1 (de) * 2002-05-01 2010-06-24 Danisco Us Inc Cytokine und cytokinrezeptoren mit reduzierter immunogenität
CA2488858A1 (en) * 2002-06-12 2003-12-24 Research Development Foundation Immunotoxin as a therapeutic agent and uses thereof
CN101597601B (zh) * 2002-06-26 2013-06-05 诺维信公司 具有改变的免疫原性的枯草杆菌酶和枯草杆菌酶变体
US20040007251A1 (en) * 2002-07-10 2004-01-15 Kimberly-Clark Worldwide, Inc. Cleaners for the control and removal of allergens
JP4694966B2 (ja) 2002-07-30 2011-06-08 ジェネンコー・インターナショナル・インク エアロゾル生成を低減する製剤
WO2004014938A2 (en) * 2002-08-09 2004-02-19 Xencor Thrombopoiesis-stimulating proteins having reduced immunogenicity
CN1774504B (zh) 2003-02-07 2013-04-17 诺维信公司 蛋白酶
WO2004078960A1 (en) 2003-02-26 2004-09-16 Genencor International, Inc. Amylases producing an altered immunogenic response and methods of making and using the same
EP2500423B1 (de) 2003-02-26 2015-06-17 Danisco US Inc. Amylasen, die eine veränderte immunogene Reaktion bewirken, und Verfahren zu ihrer Herstellung und Verwendung
EP1641813B1 (de) * 2003-07-03 2011-11-09 Avatar Biotechnologies, Inc. Verfahren zur herstellung von molekülen mit verminderter immunogenität
ES2358092T3 (es) 2003-10-10 2011-05-05 Novozymes A/S Variantes de proteasa.
JP4804357B2 (ja) 2003-11-01 2011-11-02 メルク パテント ゲーエムベーハー 改変抗ｃｄ５２抗体
ATE491025T1 (de) * 2004-04-02 2010-12-15 Novozymes As Subtilasevarianten mit veränderter immunogenität
JP2007532114A (ja) * 2004-04-09 2007-11-15 ジェネンコー・インターナショナル・インク バチルスにおけるｐｃｋＡ修飾および増強されたタンパク質発現
US8088609B2 (en) * 2004-04-15 2012-01-03 Danisco Us Inc. CAB molecules
US20080220450A1 (en) * 2004-04-26 2008-09-11 Danisco Us, Inc., Genencor Division Population Based Prediction Methods for Immune Response Determinations and Methods for Verifying Immunological Response Data
US7771999B2 (en) * 2004-04-28 2010-08-10 Vaxdesign Corp. Disease model incorporation into an artificial immune system (AIS)
JP5795699B2 (ja) 2004-04-28 2015-10-14 サノフィ パスツール ヴァックスデザイン コーポレーション 人工免疫システム：作製および使用方法
US7855074B2 (en) 2004-04-28 2010-12-21 Vaxdesign Corp. Artificial immune system: methods for making and use
US8071373B2 (en) 2004-04-28 2011-12-06 Sanofi Pasteur Vaxdesign Corp. Co-culture lymphoid tissue equivalent (LTE) for an artificial immune system (AIS)
US8298824B2 (en) 2004-04-28 2012-10-30 Sanofi Pasteur Vaxdesign Corporation Methods of evaluating a test agent in a diseased cell model
US7785883B2 (en) * 2004-04-28 2010-08-31 Vax Design Corp. Automatable artificial immune system (AIS)
US7785806B2 (en) * 2004-04-28 2010-08-31 Vaxdesign Corporation Method for determining the immunogenicity of an antigen
US7709256B2 (en) 2004-04-28 2010-05-04 Vaxdesign Corp. Disease model incorporation into an artificial immune system (AIS)
US20060275270A1 (en) * 2004-04-28 2006-12-07 Warren William L In vitro mucosal tissue equivalent
US8030070B2 (en) * 2004-04-28 2011-10-04 Sanofi Pasteur Vaxdesign Corp. Artificial lymphoid tissue equivalent
US20070141552A1 (en) * 2004-04-28 2007-06-21 Warren William L Automatable artificial immune system (AIS)
US20090060933A1 (en) * 2004-06-14 2009-03-05 Estell David A Proteases producing an altered immunogenic response and methods of making and using the same
ES2380105T3 (es) 2004-06-21 2012-05-08 Novozymes A/S Proteasas de Nocardiopsis
JP2008528668A (ja) * 2005-02-03 2008-07-31 アンチトープ リミテッド ヒト抗体及びタンパク質
EP1869192B1 (de) * 2005-03-18 2016-01-20 MedImmune, LLC Rahmenmischung von antikörpern
AU2006236905B2 (en) * 2005-04-15 2010-06-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
ES2351057T3 (es) * 2005-07-08 2011-01-31 Pfizer Limited Anticuerpos contra madcam.
ES2535426T3 (es) * 2005-08-04 2015-05-11 Janssen Biotech, Inc. Anticuerpos anti-TNFα y métodos de uso
AU2006290475A1 (en) * 2005-09-14 2007-03-22 Cambridge Antibody Technology Limited Pseudomonas exotoxin a CD4+ T-cell epitopes
AU2006331504A1 (en) * 2005-12-21 2007-07-05 Vaxdesign Corporation In vitro germinal centers
ATE531793T1 (de) * 2005-12-21 2011-11-15 Sanofi Pasteur Vaxdesign Corp Eine poröse membran gerät, das die differenzierung von monozyten in dendritische zellen fördert
EP2004803A2 (de) 2006-03-23 2008-12-24 Ajinomoto Co., Inc. Verfahren zur herstellung einer l-aminosäure unter verwendung eines bakteriums der familie enterobacteriaceae mit abgeschwächter expression eines für kleine rna codierenden gens
EP2409714A1 (de) * 2006-06-27 2012-01-25 Sanofi Pasteur VaxDesign Corporation Modelle für die Bewertung von Impfstoffen
EA200970250A1 (ru) 2006-09-05 2010-02-26 Медарекс, Инк. Антитела к костным морфогенетическим белкам и их рецепторам и способы их применения
US20080090745A1 (en) * 2006-10-13 2008-04-17 Fox Bryan P Expression of Streptomyces subtilism inhibitor (SSI) proteins in Bacillus and Streptomyces sp.
MX2009003637A (es) * 2006-10-16 2009-04-22 Danisco Us Inc Genencor Div Detergentes sin fosfato para lavar platos.
JP2010513306A (ja) 2006-12-14 2010-04-30 メダレックス インコーポレーティッド Ｃｄ７０に結合するヒト抗体およびその使用
JP5867984B2 (ja) 2007-03-12 2016-02-24 ダニスコ・ユーエス・インク 修飾プロテアーゼ
CN101679489B (zh) 2007-05-10 2014-05-28 丹尼斯科美国公司 增加细菌内多肽表达的修饰的分泌系统
WO2009014835A2 (en) 2007-06-21 2009-01-29 Angelica Therapeutics, Inc. Modified toxins
WO2009048661A1 (en) * 2007-07-16 2009-04-16 Vaxdesign Corporation Artificial tissue constructs comprising alveolar cells and methods for using the same
KR20100098652A (ko) 2007-12-21 2010-09-08 다니스코 유에스 인크. 바실루스 내에서의 향상된 단백질 생산
AU2008352548B2 (en) * 2008-03-12 2014-12-04 Sanofi Pasteur Vaxdesign Corporation Disease model incorporation into an artificial immune system (AIS)
US9528114B2 (en) * 2008-03-28 2016-12-27 Danisco Us Inc. Method for amplifying locus in bacterial cell
RU2509776C2 (ru) 2008-10-15 2014-03-20 ДАНИСКО ЮЭс ИНК. МОДИФИЦИРОВАННЫЕ ВАРИАНТЫ ИНГИБИТОРОВ ПРОТЕАЗ Bowman Birk
US7803902B2 (en) 2008-10-15 2010-09-28 Danisco Us Inc. Modified variant bowman birk protease inhibitors
US7772181B2 (en) 2008-10-15 2010-08-10 Danisco Us Inc. Personal care compositions comprising modified variant Bowman Birk Protease Inhibitors
MX339402B (es) * 2008-11-11 2016-05-25 Danisco Us Inc Composiciones y metodos que comprenden variantes de serina proteasa.
EP2362896A2 (de) 2008-11-11 2011-09-07 Danisco US Inc. Bacillus subtilisin mit mindestens einer kombinierbaren mutation
FR2940451B1 (fr) 2008-12-18 2014-09-12 Proteus Procede d'evaluation de l'immunogenicite des proteines
AR076941A1 (es) 2009-06-11 2011-07-20 Danisco Us Inc Cepa de bacillus para una mayor produccion de proteina
RU2639534C2 (ru) * 2009-09-25 2017-12-21 Новозимс А/С Применение вариантов протеазы
EP4159833A3 (de) 2009-12-09 2023-07-26 The Procter & Gamble Company Stoff- und heimpflegeprodukte
CA2902905A1 (en) 2013-03-15 2014-09-25 Claude Geoffrey Davis Modified toxins
CN106068273B (zh) 2013-12-31 2021-01-08 丹尼斯科美国公司 增强的蛋白质表达
US10627411B2 (en) 2014-03-27 2020-04-21 British Columbia Cancer Agency Branch T-cell epitope identification
KR102588719B1 (ko) 2014-12-16 2023-10-12 다니스코 유에스 인크. 향상된 단백질 발현
WO2016100128A1 (en) 2014-12-19 2016-06-23 Danisco Us Inc Enhanced protein expression
GB201501565D0 (en) * 2015-01-30 2015-03-18 Dupont Nutrition Biosci Aps Method
FI3585910T3 (fi) 2017-02-24 2024-06-19 Danisco Us Inc Koostumukset ja menetelmät proteiinin tuotannon lisäämiseksi bacillus licheniformiksessa
EP3655537A1 (de) 2017-08-23 2020-05-27 Danisco US Inc. Verfahren und zusammensetzungen zur effizienten genetischen modifikation von bacillus-licheniformis-stämmen
WO2019055261A1 (en) 2017-09-13 2019-03-21 Danisco Us Inc MODIFIED 5 'NON-TRANSLATED REGION (UTR) SEQUENCES FOR INCREASED PROTEIN PRODUCTION IN BACILLUS
CN111108195A (zh) 2017-09-27 2020-05-05 宝洁公司 包含脂肪酶的洗涤剂组合物
DE102017125560A1 (de) 2017-11-01 2019-05-02 Henkel Ag & Co. Kgaa Reinigungszusammensetzungen, die dispersine iii enthalten
WO2019089898A1 (en) 2017-11-02 2019-05-09 Danisco Us Inc Freezing point depressed solid matrix compositions for melt granulation of enzymes
WO2019135868A1 (en) 2018-01-03 2019-07-11 Danisco Us Inc Mutant and genetically modified bacillus cells and methods thereof for increased protein production
WO2021146411A1 (en) 2020-01-15 2021-07-22 Danisco Us Inc Compositions and methods for enhanced protein production in bacillus licheniformis
EP4388077A1 (de) 2021-08-20 2024-06-26 Danisco US Inc. Polynukleotide zur codierung neuartiger nukleasen, zusammensetzungen davon und verfahren zur entfernung von dna aus proteinpräparaten

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK151269C (da) 1978-07-04 1988-05-02 Novo Industri As Proteinasepraeparat med nedsat allergenicitet, fremgangsmaade til fremstilling heraf samt mikroorganismestammer til anvendelse ved fremstilling heraf
US4261868A (en) 1979-08-08 1981-04-14 Lever Brothers Company Stabilized enzymatic liquid detergent composition containing a polyalkanolamine and a boron compound
US4404128A (en) 1981-05-29 1983-09-13 The Procter & Gamble Company Enzyme detergent composition
JPS58144105A (ja) 1982-02-12 1983-08-27 Kurabo Ind Ltd スケ−ル除去獣毛繊維の製法
US4760025A (en) 1984-05-29 1988-07-26 Genencor, Inc. Modified enzymes and methods for making same
US5264366A (en) 1984-05-29 1993-11-23 Genencor, Inc. Protease deficient bacillus
US5182204A (en) 1984-05-29 1993-01-26 Genencor International, Inc. Non-human carbonyl hydrolase mutants, vectors encoding same and hosts transformed with said vectors
US5801038A (en) * 1984-05-29 1998-09-01 Genencor International Inc. Modified subtilisins having amino acid alterations
US5204015A (en) 1984-05-29 1993-04-20 Genencor International, Inc. Subtilisin mutants
US5185258A (en) 1984-05-29 1993-02-09 Genencor International, Inc. Subtilisin mutants
IE65767B1 (en) * 1986-04-30 1995-11-15 Genencor Int Non-human carbonyl hydrolase mutants DNA sequences and vectors encoding same and hosts transformed with said vectors
US5314692A (en) 1987-08-24 1994-05-24 Cultor Ltd. Enzyme premix for feed and method
WO1989004552A1 (en) 1987-10-30 1989-05-18 Lsi Logic Corporation Method and means of fabricating a semiconductor device package
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US4874070A (en) 1988-02-10 1989-10-17 Eaton Corporation Control for AMT system start from stop operation
DE3841152A1 (de) 1988-12-07 1990-06-13 Hoechst Ag Verwendung von bakterienlysierendem enzymprodukt als zusatzstoff zur verbesserung der futterverwertung in der tierproduktion
US5766898A (en) * 1990-12-05 1998-06-16 Novo Nordisk A/S Proteins with changed epitopes and methods for the production thereof
CA2095852C (en) 1990-12-05 2001-05-08 Uffe Lovborg Proteins with changed epitopes and methods for the production thereof
EP0633929B1 (de) * 1992-04-01 2004-03-03 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
AU4678993A (en) * 1992-07-16 1994-02-14 Board Of Trustees Of The Leland Stanford Junior University Methods for using dendritic cells to activate t cells
DK132892D0 (da) 1992-10-30 1992-10-30 Novo Nordisk As Proteiner
US5593877A (en) * 1993-03-11 1997-01-14 The Rockefeller University Nucleic acid and recombinant production of vespid venom hyaluronidase
US5585250A (en) * 1993-08-20 1996-12-17 The United States Of America As Represented By The Department Of Health & Human Services Dampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapies
US5820862A (en) * 1994-04-14 1998-10-13 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
GB9416841D0 (en) 1994-08-19 1994-10-12 Finnfeeds Int Ltd An enzyme feed additive and animal feed including it
US5648219A (en) * 1995-06-07 1997-07-15 Zymogenetics, Inc. Immortalized dendritic cells
AU3924095A (en) 1994-11-24 1996-06-17 Novo Nordisk A/S A process for producing polypeptides with reduced allergenicity
FI972443A7 (fi) 1994-12-07 1997-06-09 Novozymes As Polypeptidi, jonka allergeenisuus on vähentynyt
US5951980A (en) * 1995-01-06 1999-09-14 Leuven Research & Development Vzw Identification, production and use of new staphylokinase derivatives with reduced immunogenicity
US5837517A (en) * 1995-05-05 1998-11-17 Novo Nordisk A/S Protease variants and compositions
DE69637907D1 (de) 1995-05-05 2009-06-04 Novozymes As Protease-varianten und verbindungen
AU5893696A (en) 1995-06-07 1996-12-30 Novo Nordisk A/S Modification of polypeptides
JP2000506119A (ja) 1996-02-15 2000-05-23 ノボ ノルディスク アクティーゼルスカブ ポリペプチドのコンジュゲーション
US5849589A (en) * 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
ATE409743T1 (de) 1996-11-04 2008-10-15 Novozymes As Subtilase varianten und verbindungen
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
US6495136B1 (en) * 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
US6835550B1 (en) 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
CA2238660A1 (en) 1998-05-22 1999-11-22 Janet Chantler Gene sequences of rubella virus associated with attenuation
DE69916306T2 (de) * 1998-10-30 2005-05-04 Novozymes A/S Niedrigallergene proteinvarianten
GB9913425D0 (en) * 1999-06-09 1999-08-11 Universitu Libre De Bruxelles Identification and molecular characterisation of proteins expressed in the tick salivary glands

Also Published As

Publication number Publication date
US20050137112A1 (en) 2005-06-23
WO1999053038A2 (en) 1999-10-21
MXPA05003289A (es) 2005-09-08
DE69920434D1 (de) 2004-10-28
ES2229703T4 (es) 2006-07-16
IL138445A0 (en) 2001-10-31
US6218165B1 (en) 2001-04-17
BR9909640A (pt) 2000-12-19
CN1302113C (zh) 2007-02-28
US6835550B1 (en) 2004-12-28
EP1073754B9 (de) 2005-01-19
ES2338319T3 (es) 2010-05-06
ID26645A (id) 2001-01-25
PL343509A1 (en) 2001-08-27
DE69920434T2 (de) 2005-10-13
EP1997897B1 (de) 2012-11-14
JP2002511251A (ja) 2002-04-16
DK1586649T3 (da) 2010-04-26
AU752934B2 (en) 2002-10-03
CA2327311A1 (en) 1999-10-21
ES2229703T3 (es) 2005-04-16
AU3645499A (en) 1999-11-01
WO1999053038A3 (en) 2000-02-10
DK1073754T3 (da) 2005-05-09
NZ524596A (en) 2004-09-24
US6596525B1 (en) 2003-07-22
DE69920434T4 (de) 2006-07-27
CZ20003789A3 (cs) 2001-08-15
NO20005153D0 (no) 2000-10-13
NO20005153L (no) 2000-12-11
CA2327311C (en) 2010-03-16
EP1073754A2 (de) 2001-02-07
CN1297484A (zh) 2001-05-30
JP4447774B2 (ja) 2010-04-07
ATE452195T1 (de) 2010-01-15
NZ506926A (en) 2003-10-31
EP1586649A3 (de) 2005-11-02
EP1997897A1 (de) 2008-12-03
EP1586649A2 (de) 2005-10-19
DE69941827D1 (de) 2010-01-28
IL138445A (en) 2013-05-30
EP1073754B1 (de) 2004-09-22
DK1997897T3 (da) 2013-02-11
MXPA05003288A (es) 2005-09-08
KR20010034776A (ko) 2001-04-25
EP1586649B1 (de) 2009-12-16

Similar Documents

Publication Publication Date Title
ATE277189T1 (de) Verfahren zur herstellung von protein mutanten mit reduzierter allergener wirkung in menschen.
ATE378403T1 (de) Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
DE69627839D1 (de) Caseinphosphopeptide und dasselbe enthaltende casein, sowie verfahren in dessem herstellung
DE68912336D1 (de) Hydrophobe proteinmikroteilchen und verfahren zur herstellung.
DE69617921D1 (de) Verfahren zur herstellung von 1,1,1,3,3-pentafluoropropan
DE69429723D1 (de) Stressproteine und ihre verwendung
DE69801489D1 (de) Verfahren zur herstellung von 1,1,1,3,3-pentafluorpropan
DE69618476D1 (de) Verfahren zur herstellung von 1,1,1,3,3-pentafluorpropan
ATE215936T1 (de) Verfahren zur herstellung von reinem melamin
DE69622051D1 (de) Verfahren zur herstellung von 2,4-dihydroxy-pyridin und 2,4-dihydroxy-3-nitropyridin
DE68909487D1 (de) Siliconschaum mit hohem festigkeitsverhalten und verfahren zur herstellung.
NO20005152L (no) Human protease og anvendelse av slik protease for farmasöytiske anvendelser og for reduksjon av allergenisiteten til ikke-humane proteiner
DE59603431D1 (de) Verfahren zur herstellung von organisch modifizierten aerogelen und deren verwendung
DE69325452D1 (de) Verfahren zur herstellung von (s)-3-amino-1-substituiert-pirrolidine
DE59407708D1 (de) Verfahren zur herstellung von homo- und copolymerisaten von alk-1-enen
DE69717115D1 (de) Verfahren zur herstellung von 1,1,1,3,3-pentafluorpropan
DE69603261D1 (de) Verfahren zur herstellung von 1,2-benzisothiazolonen
DE69612610D1 (de) Verfahren zur herstellung von 1,1,1,3,3-pentafluoropropan
DE69711039D1 (de) Verfahren zur herstellung von 1,3-alkandiolen
DE59310372D1 (de) Verfahren zur immunchemischen Quantifizierung von inaktivierten, immunreaktiven Antigenen
ATE223659T1 (de) Verfahren zur herstellung von garnierten lebensmitteln und lebensmittel hergestellt mit diesem verfahren
DE69410085D1 (de) Verfahren zur herstellung von 1, 1, 1, 3, 3-pentafluoropropan
DE69018790D1 (de) Halbleiterdiodenlaser und Verfahren zur Herstellung desselben.
DE69010364D1 (de) Laserdiode und Verfahren zur Herstellung derselben.
DE59805434D1 (de) Verfahren zur herstellung von 2,4,5-trifluor-benzonitril

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties